文献速递妇科

复发性卵巢癌免疫治疗后的后续治疗与生存

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2019-08-14

本回顾性研究纳入2013年1月至2017年5月接受免疫检查点抑制剂(ICI)且至少接受1次后续治疗的79例复发性卵巢癌患者,其中66例(84%)为铂耐药。ICI后中位总生存期为18.3个月(95%CI,11.8-22.7),长与短ICI疗程间无差异。作者认为ICI可能改善后续化疗的疗效。

要点

  • 79例可评估患者中66例(84%)为铂耐药复发性卵巢癌。
  • ICI后首线治疗中位持续时间3.7个月(95%CI,2.9-6.0),随后续治疗线数递减。
  • ICI后中位总生存期18.3个月(95%CI,11.8-22.7),长与短ICI疗程间无差异。

核心结论

  • 在这组经过大量治疗的复发性卵巢癌患者中,ICI后的治疗带来了有希望的生存结果,提示ICI可能改善后续化疗的疗效。

研究设计与样本

  • 回顾性综述,纳入2013年1月至2017年5月接受ICI且至少接受1次后续治疗的复发性卵巢癌女性,共79例可评估。

主要发现

  • 79例中66例(84%)为铂耐药卵巢癌,诊断时中位年龄57岁。
  • 从诊断到ICI的中位时间为39.7个月,既往治疗中位数为4线(范围,1-12)。
  • ICI后治疗中位数为2线(范围,1-8),ICI后首线治疗中位持续时间3.7个月(95%CI,2.9-6.0),随后续每线递减。
  • ICI后最常用治疗为紫杉类、铂类方案和聚乙二醇脂质体多柔比星,贝伐珠单抗用于47例(59%)。
  • ICI后中位总生存期为18.3个月(95%CI,11.8-22.7),长ICI疗程(≥24周)与短ICI疗程(<24周)间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer (OC), yet little is known about their effects on subsequent treatment. Preclinical studies suggest immunotherapy may enhance response to chemotherapy. We sought to evaluate the impact of ICIs on subsequent therapies and survival in recurrent OC. METHODS: A retrospective review was conducted to identify women with recurrent OC who received ICI from 01/2013 to 5/2017 and ≥1 subsequent treatment. Treatment duration after ICI was calculated using time-to-event analysis. Kaplan-Meier survival analysis and Cox proportional hazards models were used to calculate overall survival (OS) from first treatment after ICI and to assess survival differences by clinical benefit from ICI, defined by long (≥24 weeks) versus short (<24 weeks) ICI treatment duration. RESULTS: Of 79 evaluable women identified, 66 (84%) had platinum-resistant OC. Median age at diagnosis was 57 years. Median time from diagnosis to ICI was 39.7 months, with median of 4 prior treatments (range, 1-12). Median number of treatments after ICI was 2 (range, 1-8). Median duration of first-line treatment after ICI was 3.7 months (95% CI, 2.9-6.0) and declined with each subsequent line. The most common therapies after ICI were taxanes, platinum-based regimens, and pegylated liposomal doxorubicin. Bevacizumab was used in 47 women (59%). Median OS after ICI was 18.3 months (95% CI, 11.8-22.7) and did not differ between long versus short ICI. CONCLUSIONS: In this heavily pretreated population of patients with recurrent OC, therapies after ICI resulted in promising survival, suggesting that ICI may improve efficacy of subsequent chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Liu YL, Zhou Q, Iasonos A, et al. Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecol Oncol. 2019. PMID: 31421916. doi:10.1016/j.ygyno.2019.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。